IO Biotech, Inc.
IOBTDelisted Jun 8, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001865494
IO Biotech, Inc. was delisted on Jun 8, 2026; its insiders filed their last Form 4 on Jun 6, 2025; 12 institutions reported holding it in 13F filings for Q1 2026, worth $199.0K in total; no superinvestor held it.
13F holders, Q3 2023
Institutional positions in IO Biotech, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +4 vs. Q2 2023
- Shares held
- 29.7M
- +17.4M (+142.3%) vs. Q2 2023
- Total value
- $41.7M
- +$17.7M (+74.1%) vs. Q2 2023
- New holders
- 8
- 4 more added
- Sold out
- 4
- 2 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IOBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 12 | $199.0K |
| Q4 2025 | 22 | $4.78M |
| Q3 2025 | 21 | $3.59M |
| Q2 2025 | 26 | $25.3M |
| Q1 2025 | 22 | $20.8M |
| Q4 2024 | 27 | $18.2M |
| Q3 2024 | 20 | $24.8M |
| Q2 2024 | 20 | $30.7M |
| Q1 2024 | 18 | $47.4M |
| Q4 2023 | 18 | $55.3M |
| Q3 2023 | 19 | $41.7M |
| Q2 2023 | 15 | $24.0M |
| Q1 2023 | 17 | $26.1M |
| Q4 2022 | 17 | $32.8M |
| Q3 2022 | 21 | $41.6M |
| Q2 2022 | 18 | $72.2M |
| Q1 2022 | 19 | $76.9M |
| Q4 2021 | 20 | $92.6M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding IO Biotech, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ancora Advisors, LLC | 908 | $1.28K | 0.00% | 00.0% | Unchanged |
| Wealth Enhancement Advisory Services, LLC | 10,100 | $14.2K | 0.00% | +10,100 | New |
| Geode Capital Management, LLC | 12,730 | $17.6K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 21,238 | $29.3K | 0.01% | +21,238 | New |
| Renaissance Technologies LLC | 24,386 | $34.0K | 0.00% | −44,714−64.7% | Reduced |
| Morgan Stanley | 68,813 | $97.0K | 0.00% | −135−0.2% | Reduced |
| Bridgeway Capital Management, LLC | 132,200 | $182.4K | 0.00% | 00.0% | Unchanged |
| Logos Global Management LP | 493,827 | $696.3K | 0.10% | +493,827 | New |
| Pivotal bioVenture Partners Investment Advisor LLC | 864,197 | $1.22M | 0.49% | +864,197 | New |
| Alyeska Investment Group, L.P. | 987,654 | $1.39M | 0.01% | +987,654 | New |
| PFM Health Sciences, LP | 1,353,453 | $1.91M | 0.09% | +740,740+120.9% | Added |
| Bank of America Corp | 1,854,185 | $2.61M | 0.00% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 1,975,308 | $2.79M | 0.93% | +1,975,308 | New |
| Avoro Capital Advisors LLC | 2,055,883 | $2.84M | 0.04% | 00.0% | Unchanged |
| Marshall Wace, LLP | 2,105,262 | $2.91M | 0.01% | +2,105,262 | New |
| Armistice Capital, LLC | 2,148,000 | $3.03M | 0.09% | +2,148,000 | New |
| Samsara BioCapital, LLC | 3,640,015 | $5.13M | 1.57% | +2,631,578+261.0% | Added |
| Novo Holdings A/S | 5,747,067 | $8.10M | 0.60% | +2,469,135+75.3% | Added |
| Vivo Capital, LLC | 6,173,439 | $8.70M | 1.08% | +3,157,894+104.7% | Added |
| Aureus Asset Management, LLC | 0 | $0 | 0.00% | −43,744−100.0% | Sold out |
| Summit Trail Advisors, LLC | 0 | $0 | 0.00% | −43,744−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −37,690−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −13,020−100.0% | Sold out |